AQUESTIVE THERAPEUTICS INC (AQST) Fundamental Analysis & Valuation

NASDAQ:AQST • US03843E1047

Current stock price

4.32 USD
+0.06 (+1.41%)
At close:
4.3 USD
-0.02 (-0.46%)
After Hours:

This AQST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AQST Profitability Analysis

1.1 Basic Checks

  • In the past year AQST has reported negative net income.
  • In the past year AQST has reported a negative cash flow from operations.
  • In the past 5 years AQST always reported negative net income.
  • In the past 5 years AQST always reported negative operating cash flow.
AQST Yearly Net Income VS EBIT VS OCF VS FCFAQST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M

1.2 Ratios

  • AQST has a Return On Assets of -52.23%. This is in the lower half of the industry: AQST underperforms 65.97% of its industry peers.
Industry RankSector Rank
ROA -52.23%
ROE N/A
ROIC N/A
ROA(3y)-36.48%
ROA(5y)-63.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQST Yearly ROA, ROE, ROICAQST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • AQST's Gross Margin of 58.35% is fine compared to the rest of the industry. AQST outperforms 67.54% of its industry peers.
  • AQST's Gross Margin has declined in the last couple of years.
  • AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.56%
GM growth 5Y-4.05%
AQST Yearly Profit, Operating, Gross MarginsAQST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AQST Health Analysis

2.1 Basic Checks

  • AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AQST has been increased compared to 1 year ago.
  • AQST has more shares outstanding than it did 5 years ago.
  • AQST has a better debt/assets ratio than last year.
AQST Yearly Shares OutstandingAQST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
AQST Yearly Total Debt VS Total AssetsAQST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • AQST has an Altman-Z score of -2.69. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.69, AQST is doing worse than 61.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.69
ROIC/WACCN/A
WACC9.05%
AQST Yearly LT Debt VS Equity VS FCFAQST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that AQST has no problem at all paying its short term obligations.
  • AQST has a Current ratio (3.14) which is in line with its industry peers.
  • AQST has a Quick Ratio of 3.01. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.01, AQST is in line with its industry, outperforming 53.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.01
AQST Yearly Current Assets VS Current LiabilitesAQST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AQST Growth Analysis

3.1 Past

  • The earnings per share for AQST have decreased strongly by -28.85% in the last year.
  • AQST shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.61%.
  • The Revenue has been decreasing by -0.58% on average over the past years.
EPS 1Y (TTM)-28.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
Revenue 1Y (TTM)-22.61%
Revenue growth 3Y-2.24%
Revenue growth 5Y-0.58%
Sales Q2Q%20.93%

3.2 Future

  • Based on estimates for the next years, AQST will show a very strong growth in Earnings Per Share. The EPS will grow by 23.41% on average per year.
  • AQST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.01% yearly.
EPS Next Y27.36%
EPS Next 2Y16.54%
EPS Next 3Y14.93%
EPS Next 5Y23.41%
Revenue Next Year7.28%
Revenue Next 2Y26.69%
Revenue Next 3Y34.73%
Revenue Next 5Y42.01%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AQST Yearly Revenue VS EstimatesAQST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
AQST Yearly EPS VS EstimatesAQST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. AQST Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AQST. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AQST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQST Price Earnings VS Forward Price EarningsAQST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQST Per share dataAQST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • AQST's earnings are expected to grow with 14.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.54%
EPS Next 3Y14.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AQST Dividend Analysis

5.1 Amount

  • AQST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AQST Fundamentals: All Metrics, Ratios and Statistics

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (4/17/2026, 8:00:02 PM)

After market: 4.3 -0.02 (-0.46%)

4.32

+0.06 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04
Earnings (Next)05-05
Inst Owners61.44%
Inst Owner Change0.4%
Ins Owners3.54%
Ins Owner Change9.12%
Market Cap527.26M
Revenue(TTM)44.55M
Net Income(TTM)-83.78M
Analysts84
Price Target9.07 (109.95%)
Short Float %15.14%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.29%
Min EPS beat(2)-10.99%
Max EPS beat(2)-3.59%
EPS beat(4)1
Avg EPS beat(4)-8.63%
Min EPS beat(4)-38.41%
Max EPS beat(4)18.46%
EPS beat(8)2
Avg EPS beat(8)-12.32%
EPS beat(12)5
Avg EPS beat(12)-0.39%
EPS beat(16)9
Avg EPS beat(16)3.15%
Revenue beat(2)0
Avg Revenue beat(2)-3.47%
Min Revenue beat(2)-3.95%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-12.6%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)-2.99%
Revenue beat(8)2
Avg Revenue beat(8)-1.19%
Revenue beat(12)4
Avg Revenue beat(12)0.67%
Revenue beat(16)8
Avg Revenue beat(16)3.27%
PT rev (1m)-3.61%
PT rev (3m)-1.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.37%
EPS NY rev (1m)16.92%
EPS NY rev (3m)12.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-24.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.36
BVpS-0.28
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -52.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.35%
FCFM N/A
ROA(3y)-36.48%
ROA(5y)-63.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.56%
GM growth 5Y-4.05%
F-Score2
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.56%
Cap/Sales 1.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 3.01
Altman-Z -2.69
F-Score2
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)66.23%
Cap/Depr(5y)66.97%
Cap/Sales(3y)1.17%
Cap/Sales(5y)2.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
EPS Next Y27.36%
EPS Next 2Y16.54%
EPS Next 3Y14.93%
EPS Next 5Y23.41%
Revenue 1Y (TTM)-22.61%
Revenue growth 3Y-2.24%
Revenue growth 5Y-0.58%
Sales Q2Q%20.93%
Revenue Next Year7.28%
Revenue Next 2Y26.69%
Revenue Next 3Y34.73%
Revenue Next 5Y42.01%
EBIT growth 1Y-127.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.32%
EBIT Next 3Y22.47%
EBIT Next 5Y38.79%
FCF growth 1Y-47.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.63%
OCF growth 3YN/A
OCF growth 5YN/A

AQUESTIVE THERAPEUTICS INC / AQST Fundamental Analysis FAQ

What is the fundamental rating for AQST stock?

ChartMill assigns a fundamental rating of 2 / 10 to AQST.


What is the valuation status for AQST stock?

ChartMill assigns a valuation rating of 0 / 10 to AQUESTIVE THERAPEUTICS INC (AQST). This can be considered as Overvalued.


Can you provide the profitability details for AQUESTIVE THERAPEUTICS INC?

AQUESTIVE THERAPEUTICS INC (AQST) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AQST stock?

The Earnings per Share (EPS) of AQUESTIVE THERAPEUTICS INC (AQST) is expected to grow by 27.36% in the next year.